Cochrane Abstracts
Effectiveness and safety of first‐line tenofovir + emtricitabine + efavirenz for patients with HIV
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Effectiveness and Safety of First‐line Tenofovir + Emtricitabine + Efavirenz for Patients With HIV." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438093/all/Effectiveness_and_safety_of_first‐line_tenofovir_+_emtricitabine_+_efavirenz_for_patients_with_HIV.
Effectiveness and safety of first‐line tenofovir + emtricitabine + efavirenz for patients with HIV. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438093/all/Effectiveness_and_safety_of_first‐line_tenofovir_+_emtricitabine_+_efavirenz_for_patients_with_HIV. Accessed April 21, 2026.
Effectiveness and safety of first‐line tenofovir + emtricitabine + efavirenz for patients with HIV. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438093/all/Effectiveness_and_safety_of_first‐line_tenofovir_+_emtricitabine_+_efavirenz_for_patients_with_HIV
Effectiveness and Safety of First‐line Tenofovir + Emtricitabine + Efavirenz for Patients With HIV [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 April 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438093/all/Effectiveness_and_safety_of_first‐line_tenofovir_+_emtricitabine_+_efavirenz_for_patients_with_HIV.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Effectiveness and safety of first‐line tenofovir + emtricitabine + efavirenz for patients with HIV
ID - 438093
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438093/all/Effectiveness_and_safety_of_first‐line_tenofovir_+_emtricitabine_+_efavirenz_for_patients_with_HIV
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
